Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Diabetes Care · 2026-06-01 · 49 (6) · 1134-1143
DOI: 10.2337/dc25-2435 ↗Abstract
BACKGROUND Automated insulin delivery (AID) systems are the standard of care in type 1 diabetes. Recent studies suggest benefits of these systems for people with type 2 diabetes, as well. PURPOSE To evaluate the effects of AID systems on glycemic outcomes in people with type 2 diabetes requiring insulin. DATA SOURCES The PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched through 10 March 2025. This study was registered with PROSPERO (CRD420251036184). STUDY SELECTION Nine studies (n = 1,530 participants) were included that evaluated AID systems in people with type 2 diabetes reporting continuous glucose monitoring outcomes. DATA EXTRACTION Data were collected on study characteristics and outcomes including time in range (TIR) (3.9–10.0 mmol/L [70–180 mg/dL]), time above range (TAR) (>10.0 mmol/L [>180 mg/dL]), time below range (TBR) (<3.9 mmol/L [<70 mg/dL]), mean glucose, and HbA1c. We performed a single-arm meta-analysis using a random-effects model. DATA SYNTHESIS AID systems significantly increased TIR by 16.06% (95% CI 10.48–21.65), changed TAR by −15.90% (95% CI –21.44 to –10.36), changed HbA1c by −1.27% (95% CI –2.06 to –0.48), and changed mean glucose by −21.34 mg/dL (95% CI –32.06 to –10.62) or 1.19 mmol/L (95% CI –1.78 to –0.59). There was a modest yet significant reduction in TBR. There were no changes in body weight or BMI. LIMITATIONS Heterogeneous study designs, including only three randomized controlled trials, and imputed missing data. CONCLUSIONS AID systems improved glucose control in a diverse population of individuals with type 2 diabetes requiring insulin therapy with reduction in hypoglycemia. These findings support recommendations for AID systems use in future type 2 diabetes management guidelines.
EUVIMED